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Introduction 
Diffuse panbronchiolitis (DPB) is a disease with chronic 
inflammation that is exclusively located in the region of the 
respiratory bronchioles (1). The pathological features of 
this disease are characterized by a thickening of the wall of 
the respiratory bronchioles due to the infiltration of lym- 
phocytes, plasma cells, and histiocytes (1). The disease is 
prevalent in Mongolians and its prognosis is considered to 
be poor when not properly treated. Although DPB has been 
treated with corticosteroids, most patients ultimately suffer 
from a colonization of Pseudomonas aeruginosa. To avoid 
such a complication, ‘low-dose and long-term’ erythromy- 
tin treatment has been introduced as an effective regimen 
for DPB, but the effectiveness of this treatment still remains 
to be elucidated (2). 
Case Report 
A 23-year-old man was admitted to the hospital because of 
an exacerbation of a productive cough, and a fever of 
38.6”C. He had a long history of cough, purulent sputum, 
and paranasal sinusitis beginning in his youth. The patient 
had a reddish complexion and complained of dyspnoea. 
However, he had no history of bronchial asthma. The chest 
was symmetric, and normally resonant. On auscultation, 
scattered rales and rhonchi were heard, mainly in the lower 
lung fields. A haematological examination showed the 
white blood cell count to be 18 000 yl - ‘, with 87% 
neutrophils, 13% lymphocytes. The value of the C-reactive 
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protein (CRP) was 4.4 mg dl - ‘. The blood chemistry find- 
ings were all within the normal limits except for a slightly 
elevated y-globulin (21.7%). His IgE titre was within the 
normal limit. A chest X-ray showed a nodular and reticular 
shadow predominantly located at the bilateral lower lung 
fields associated with the tram line, thus suggesting 
bronchiectatic changes. Computed tomography (CT) of 
the thorax exhibited diffusely disseminated fine nodular 
shadows at the bilateral lower lung fields and bronchiectatic 
changes in the left lower lobe (Plate 1). His vital capacity 
was 2970 ml, 69% of the predicted value and FEV,, 69% of 
his forced vital capacity. The PaO, was 66.4 mmHg; 
PaCO,, 40.2 mmHg; and pH, 7.419 breathing room air. 
Parenteral administration of ampicillin was started and the 
patient became afebrile 2 days later. The CRP value and 
white blood cell count improved to 1.1 mg dl - ’ and 
8540 ,u-‘, respectively; however, improvements were 
incompletely observed on the auscultatory findings or chest 
roentgenogram. A transbronchial biopsy was carried out 
under a possible diagnosis of diffuse panbronchiolitis. As 
shown in Plate 2, the alveolar wall near the bronchiole was 
thickened due to the histiocytic accumulation and chronic 
inflammatory cell infiltrate composed of lymphocytes, 
plasma cells, and scattered eosinophils. The bronchial wall 
showed no serious changes except for a mild chronic 
inflammatory cell infiltrate. 
Under the diagnosis of DPB at an early stage, the 
administration of macrolide antibiotics (clarithromycin, 
400 mg day- ‘) was started. Six months later, he had 
another acute exacerbation of an airway infection and 
demonstrated the following levels at admission: CRP, 
4.2 mg dl - ‘; WBC 11 800 pl- ’ with 74% neutrophils, 25% 
lymphocytes, and 1% eosinophil. The parenteral admin- 
istration of cefmetazole effectively ameliorated this episode. 
The oral administration of macrolide antibiotics continued 
for a further year. However, the patient continued to 
complain of coughing, sputum production and no further 
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PLATE 1. Roentgenographic findings: (a) and (d) on the first admission. The patient was treated with clarithromycin 
(400 mg day- ‘) for 1.5 years. (b) Just before the addition of pranlukast, and (c) and (e) 8 months after the start of the 
combined administration of pranlukast (225 mg day - ‘) and clarithromycin (200 mg day - I). 
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PLATE 2. Histological findings of the alveolar and 
bronchial tissue specimens obtained by a transbronchial 
lung biopsy: (a) alveolar tissue near the bronchiole. The 
alveolar wall near the bronchiole is thickened due to 
histiocytic accumulation and chronic inflammatory cell 
infiltrate composed of lymphocytes, plasma cells and 
scattered eosinophils. The arrows reveal eosinophils. 
(H&E staining, original magnification X 100.) 
(b) Bronchus: the bronchial wall shows no serious 
changes except for some mild chronic inflammatory cell 
infiltrate. (H&E staining, original magnification x 100.) 
absorption was observed on a chest roentgenogram (Plate 
1). Leukotriene D,/E, receptor antagonist (pranlukast 
112.5 mg C - i, 2C, 2 x ) was added to the macrolide pre- 
scription (clarithromycin, 200 mg day - ‘). Six months later, 
the patient’s coughing and sputum production both 
decreased, while 2 months thereafter, another chest roent- 
genogram showed the complete disappearance of diffuse 
fine nodular shadows in association with a normalized lung 
function study (Plate 1). 
Discussion 
DPB is one of the important sinobronchial disorders in 
Mongolians (1). DPB shows a poor prognosis without 
treatment (2). The administration of corticosteroids tran- 
siently improves the subjective and objective findings, but 
patients often suffer from an airway-superinfection with 
P. aeruginosu. Although low-dose and long-term macrolide 
treatment has been reported to be effective treatment in 
DPB, its effect remains incomplete and the mechanism for 
this is not yet clear (2). Many investigators suggest that this 
drug might act as an anti-inflammatory agent rather than as 
an antibacterial one (3). 
Pranlukast (a selective LTDdEh receptor antagonist) has 
been found to be effective for the treatment of bronchial 
asthma (4). In this case, the time (6-8 months) needed for 
the symptoms and shadow on the chest X-ray to disappear 
after the initiation of the additional administration of 
pranlukast may correspond to the anti-inflammatory action 
of this drug. Cysteinyl-LTs (LTC,, D,, E4) are one of the 
most important mediators released by eosinophils and have 
chemotactic activity for themselves (4,5). Even though 
our findings remain speculative, this study suggests that 
pranlukast may also be effective in treating another chronic 
airway disorder, DPB. These results may also be compat- 
ible with the histological findings of a scattered infiltration 
of eosinophils in the peribronchiolar inflammatory lesion in 
this case. Cysteinyl-LTs are thus suggested to play a 
significant role in the inflammation of DPB. However, it 
should be noted that controlled trials are still needed to 
establish any clear effect of cysteinyl-LTs in DPB. This 
combination regimen with a low-dose of macrolide anti- 
biotics combined with a low-dose of a LTDdE, receptor 
antagonist may therefore prove to be an effective treatment 
modality for DPB. 
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